Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies

Mariona Font-Llitjós, Lídia Feliubadaló, Meritxell Espino Guarch, Ramon Clèries, Sandra Mañas, Isabelle M. Frey, Sara Puertas, Guillem Colell, Sergio Palomo, Jessica Aranda, Joana Visa, Manuel Palacín, Virginia Nunes

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cystinuria is a hereditary disorder caused by a defect in the apical membrane transport system for cystine and dibasic amino acids in renal proximal tubules and intestine, resulting in recurrent urolithiasis. Mutations in SLC3A1 and SLC7A9 genes, that codify for rBAT/b0,+ AT transporter subunits, cause type A and B cystinuria, respectively. In humans, cystinuria treatment is based on the prevention of calculi formation and its dissolution or breakage. Persistent calculi are treated with thiols [i.e., D-penicillamine (DP) and mercaptopropionylglycine (MPG)] for cystine solubilization. We have developed a new protocol with DP to validate our Slc7a9 knockout mouse model for the study of the therapeutic effect of drugs in the treatment of cystine lithiasis. We performed a 5-wk treatment of individually caged lithiasic mutant mice with a previously tested DP dose. To appraise the evolution of lithiasis throughout the treatment a noninvasive indirect method of calculi quantification was developed: calculi mass was quantified by densitometry of X-ray images from cystinuric mice before and after treatment. Urine was collected in metabolic cage experiments to quantify amino acids in DP-treated and nontreated, nonlithiasic mutant mice. We found significant differences between DP-treated and nontreated knockout mice in calculi size and in urinary cystine excretion. Histopathological analysis showed that globally nontreated mutant mice had more severe and diffuse urinary system damage than DP-treated mice. Our results validate the use of this mouse model for testing the efficacy of potential new drugs against cystinuria.

Original languageEnglish
JournalAmerican Journal of Physiology - Renal Physiology
Volume293
Issue number3
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Fingerprint

Cystinuria
Penicillamine
Knockout Mice
Calculi
Cystine
Pharmacology
Lithiasis
Diamino Amino Acids
Tiopronin
Proximal Kidney Tubule
Urolithiasis
Photon Absorptiometry
Therapeutic Uses
Sulfhydryl Compounds
Pharmaceutical Preparations
Intestines
Urine
Amino Acids
Mutation
Membranes

Keywords

  • Calculi
  • Cystinuria model
  • D-penicillamine treatment
  • Noninvasive imaging system

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies. / Font-Llitjós, Mariona; Feliubadaló, Lídia; Espino Guarch, Meritxell; Clèries, Ramon; Mañas, Sandra; Frey, Isabelle M.; Puertas, Sara; Colell, Guillem; Palomo, Sergio; Aranda, Jessica; Visa, Joana; Palacín, Manuel; Nunes, Virginia.

In: American Journal of Physiology - Renal Physiology, Vol. 293, No. 3, 09.2007.

Research output: Contribution to journalArticle

Font-Llitjós, M, Feliubadaló, L, Espino Guarch, M, Clèries, R, Mañas, S, Frey, IM, Puertas, S, Colell, G, Palomo, S, Aranda, J, Visa, J, Palacín, M & Nunes, V 2007, 'Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies', American Journal of Physiology - Renal Physiology, vol. 293, no. 3. https://doi.org/10.1152/ajprenal.00121.2007
Font-Llitjós, Mariona ; Feliubadaló, Lídia ; Espino Guarch, Meritxell ; Clèries, Ramon ; Mañas, Sandra ; Frey, Isabelle M. ; Puertas, Sara ; Colell, Guillem ; Palomo, Sergio ; Aranda, Jessica ; Visa, Joana ; Palacín, Manuel ; Nunes, Virginia. / Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies. In: American Journal of Physiology - Renal Physiology. 2007 ; Vol. 293, No. 3.
@article{ebedb27693e046568fe253a21b61ff10,
title = "Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies",
abstract = "Cystinuria is a hereditary disorder caused by a defect in the apical membrane transport system for cystine and dibasic amino acids in renal proximal tubules and intestine, resulting in recurrent urolithiasis. Mutations in SLC3A1 and SLC7A9 genes, that codify for rBAT/b0,+ AT transporter subunits, cause type A and B cystinuria, respectively. In humans, cystinuria treatment is based on the prevention of calculi formation and its dissolution or breakage. Persistent calculi are treated with thiols [i.e., D-penicillamine (DP) and mercaptopropionylglycine (MPG)] for cystine solubilization. We have developed a new protocol with DP to validate our Slc7a9 knockout mouse model for the study of the therapeutic effect of drugs in the treatment of cystine lithiasis. We performed a 5-wk treatment of individually caged lithiasic mutant mice with a previously tested DP dose. To appraise the evolution of lithiasis throughout the treatment a noninvasive indirect method of calculi quantification was developed: calculi mass was quantified by densitometry of X-ray images from cystinuric mice before and after treatment. Urine was collected in metabolic cage experiments to quantify amino acids in DP-treated and nontreated, nonlithiasic mutant mice. We found significant differences between DP-treated and nontreated knockout mice in calculi size and in urinary cystine excretion. Histopathological analysis showed that globally nontreated mutant mice had more severe and diffuse urinary system damage than DP-treated mice. Our results validate the use of this mouse model for testing the efficacy of potential new drugs against cystinuria.",
keywords = "Calculi, Cystinuria model, D-penicillamine treatment, Noninvasive imaging system",
author = "Mariona Font-Llitj{\'o}s and L{\'i}dia Feliubadal{\'o} and {Espino Guarch}, Meritxell and Ramon Cl{\`e}ries and Sandra Ma{\~n}as and Frey, {Isabelle M.} and Sara Puertas and Guillem Colell and Sergio Palomo and Jessica Aranda and Joana Visa and Manuel Palac{\'i}n and Virginia Nunes",
year = "2007",
month = "9",
doi = "10.1152/ajprenal.00121.2007",
language = "English",
volume = "293",
journal = "American Journal of Physiology - Renal Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies

AU - Font-Llitjós, Mariona

AU - Feliubadaló, Lídia

AU - Espino Guarch, Meritxell

AU - Clèries, Ramon

AU - Mañas, Sandra

AU - Frey, Isabelle M.

AU - Puertas, Sara

AU - Colell, Guillem

AU - Palomo, Sergio

AU - Aranda, Jessica

AU - Visa, Joana

AU - Palacín, Manuel

AU - Nunes, Virginia

PY - 2007/9

Y1 - 2007/9

N2 - Cystinuria is a hereditary disorder caused by a defect in the apical membrane transport system for cystine and dibasic amino acids in renal proximal tubules and intestine, resulting in recurrent urolithiasis. Mutations in SLC3A1 and SLC7A9 genes, that codify for rBAT/b0,+ AT transporter subunits, cause type A and B cystinuria, respectively. In humans, cystinuria treatment is based on the prevention of calculi formation and its dissolution or breakage. Persistent calculi are treated with thiols [i.e., D-penicillamine (DP) and mercaptopropionylglycine (MPG)] for cystine solubilization. We have developed a new protocol with DP to validate our Slc7a9 knockout mouse model for the study of the therapeutic effect of drugs in the treatment of cystine lithiasis. We performed a 5-wk treatment of individually caged lithiasic mutant mice with a previously tested DP dose. To appraise the evolution of lithiasis throughout the treatment a noninvasive indirect method of calculi quantification was developed: calculi mass was quantified by densitometry of X-ray images from cystinuric mice before and after treatment. Urine was collected in metabolic cage experiments to quantify amino acids in DP-treated and nontreated, nonlithiasic mutant mice. We found significant differences between DP-treated and nontreated knockout mice in calculi size and in urinary cystine excretion. Histopathological analysis showed that globally nontreated mutant mice had more severe and diffuse urinary system damage than DP-treated mice. Our results validate the use of this mouse model for testing the efficacy of potential new drugs against cystinuria.

AB - Cystinuria is a hereditary disorder caused by a defect in the apical membrane transport system for cystine and dibasic amino acids in renal proximal tubules and intestine, resulting in recurrent urolithiasis. Mutations in SLC3A1 and SLC7A9 genes, that codify for rBAT/b0,+ AT transporter subunits, cause type A and B cystinuria, respectively. In humans, cystinuria treatment is based on the prevention of calculi formation and its dissolution or breakage. Persistent calculi are treated with thiols [i.e., D-penicillamine (DP) and mercaptopropionylglycine (MPG)] for cystine solubilization. We have developed a new protocol with DP to validate our Slc7a9 knockout mouse model for the study of the therapeutic effect of drugs in the treatment of cystine lithiasis. We performed a 5-wk treatment of individually caged lithiasic mutant mice with a previously tested DP dose. To appraise the evolution of lithiasis throughout the treatment a noninvasive indirect method of calculi quantification was developed: calculi mass was quantified by densitometry of X-ray images from cystinuric mice before and after treatment. Urine was collected in metabolic cage experiments to quantify amino acids in DP-treated and nontreated, nonlithiasic mutant mice. We found significant differences between DP-treated and nontreated knockout mice in calculi size and in urinary cystine excretion. Histopathological analysis showed that globally nontreated mutant mice had more severe and diffuse urinary system damage than DP-treated mice. Our results validate the use of this mouse model for testing the efficacy of potential new drugs against cystinuria.

KW - Calculi

KW - Cystinuria model

KW - D-penicillamine treatment

KW - Noninvasive imaging system

UR - http://www.scopus.com/inward/record.url?scp=34548607872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548607872&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00121.2007

DO - 10.1152/ajprenal.00121.2007

M3 - Article

VL - 293

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 1931-857X

IS - 3

ER -